[SGP] Details Of Promising Cancer Therapy Shows For The First Time
Visualization of action could lead to development of more potent, less
toxic drugs
Scientists at Schering-Plough Research Institute are reporting what they say is
the first atomic view that shows how a promising new class of cancer-fighting
drugs works. The discovery may point the way to faster, better refinement of
the drugs, according to the researchers. Several pharmaceutical companies
are in a race to develop so-called farnesyl protein transferase (FPT) inhibitors,
which incapacitate an enzyme recently found to activate many types of cancer.
The drug detailed in this study is currently in clinical trials.
The findings will appear in the Journal of Medicinal Chemistry, which is
published by the American Chemical Society (ACS), the world's largest
scientific society. The peer-reviewed paper will be available on the ACS Web
June 2 and is tentatively scheduled to appear in the journal's July 1 print
edition.
FPT puts the finishing touches on a protein made under the direction of a
mutated gene called ras (short for "rat sarcoma" because the gene's cancer
connection was originally discovered in rats). Normally, a completed Ras
protein attaches to cell membranes where it signals cells to grow, when
appropriate. The mutation, which causes a single kink in the Ras protein
structure, leaves it stuck in the "on" position. Out of control growth then
ensues, causing cancer.
Since the gene's discovery in the early 1990s, the ras mutation has been linked
to 90 percent of pancreatic cancers, 50 percent of colon cancers, and 30
percent of lung cancers. Researchers hope that by attacking FPT, instead of
cell replication machinery directly, they can more specifically inhibit cancer and
lessen collateral damage to normal cells.
A wave of FPT inhibitors has recently surged into clinical trials. They are one
of the first types of mechanism-based anti-cancer agents targeted at a known
protein molecule. While scientists had ideas about how FPT inhibitors fouled
up the enzyme, the current study used crystallographic analysis to actually
view the interaction. "It is a validation that these compounds do bind to the
active site of the farnesyl protein transferase," according to co-author and
Schering-Plough Research Institute chemist Patricia Weber, Ph.D. The study
specifically looks at Schering-Plough's clinical candidate, SCH 66336, which
is in phase II efficacy trials directed against a variety of solid tumors. While the
company maintains that no trial results are available yet, Weber says the new
images "allow a detailed understanding of how and why these inhibitors work
-- and it is our expectation that, in the future, the combination of synthetic
chemistry and x-ray crystallography will lead to the development of more
potent, second generation FPT inhibitors."
Among the other pharmaceutical companies developing FPT inhibitors are
Johnson & Johnson, Merck, Bristol-Myers Squibb, Warner-Lambert, Abbott
Laboratories and Rhone-Poulenc Rorer, Inc.
|
